Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Pharmacogenetic Footprint of ACE Inhibition: A Population-Based Metabolomics Study.

PloS one - 1 Jan 2016

Altmaier Elisabeth, Menni Cristina, Heier Margit, Meisinger Christa, Thorand Barbara, Quell Jan, Kobl Michael, Römisch-Margl Werner, Valdes Ana M, Mangino Massimo, Waldenberger Melanie, Strauch Konstantin, Illig Thomas, Adamski Jerzy, Spector Tim, Gieger Christian, Suhre Karsten, Kastenmüller Gabi

Abstract excerpt

Angiotensin-I-converting enzyme (ACE) inhibitors are an important class of antihypertensives whose action on the human organism is still not fully understood. Although it is known that ACE especially cleaves COOH-terminal dipeptides from active polypeptides, the whole range of substrates and products is still unknown. When analyzing the action of ACE inhibitors, effects of genetic variation on metabolism need to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Pressure

Share to Dipeptides

Share to Metabolome

Share to Metabolomics

Share to Oligopeptides

Share to Peptidyl-Dipeptidase A

Source

Open in PubMed Open full text

Identifiers

PMID: 27120469
DOI: 10.1371/journal.pone.0153163
PMCID: PMC4847917

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Pharmacogenetic Footprint of ACE Inhibition: A Population-Based Metabolomics Study.PMID 27120469Read ↗

Pharmacogenomics And Hypertension: Current InsightsSemantic proximity Read ↗

Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations.Semantic proximity Read ↗

ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?Semantic proximity Read ↗

Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers.Semantic proximity Read ↗

Genomic and metabolomic profile associated to microalbuminuria.Semantic proximity Read ↗

Benefits of Pharmacogenetics in the Management of HypertensionSemantic proximity Read ↗

Phenotyping Angiotensin-Converting Enzyme in Blood: A Necessary Approach for Precision Medicine.Semantic proximity Read ↗

From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.Semantic proximity Read ↗

ACE insertion/deletion polymorphism and its relationships to the components of metabolic syndrome in elderly Slovaks.Semantic proximity Read ↗

Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?Semantic proximity Read ↗

Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study.Semantic proximity Read ↗

ACE genotype and ACE inhibitor response in kidney disease: a perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.